Truvestments Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Truvestments Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10	Closed	–	–	220
2021 Q4	$0	Buy	+10	New	+$132	﹤0.01%	606

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Truvestments Capital's BCRX Position: Q1 2022 in Review

Truvestments Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2022, closing a stake of 10 shares.

Truvestments Capital first reported a position in BCRX in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 233 funds tracked by Wall St. Rank hold BCRX as of Q1 2022.

Truvestments Capital reported no remaining BioCryst Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Truvestments Capital sold 10 BioCryst Pharmaceuticals shares in Q1 2022.
Truvestments Capital first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Truvestments Capital's BioCryst Pharmaceuticals position peaked at $0 in Q4 2021.
233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2022.

Based on Truvestments Capital's 13F filing for Q1 2022, filed 2 May 2022.